Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative

Journal of Ethnopharmacology

Volumn 157, Issue , 2014, Pages 105-113

  Yang, Xian ^a   Yuan, Liuliu ^a   Xiong, Chaomei ^a   Yin, Chunping ^a   Ruan, Jinlan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Abacopteris penangiana; Apoptosis; Benign prostatic hyperplasia; Inflammatory responses; Oxidative stress

Indexed keywords

ABACOPTERIS PENANGIANA EXTRACT; ACID HYDROLASE; ANDROSTANOLONE; CATALASE; CYCLOOXYGENASE 2; FLAVONOID GLYCOSIDE; GLUTATHIONE PEROXIDASE; I KAPPA B; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN BCL 2; STEROID 5ALPHA REDUCTASE; SUPEROXIDE DISMUTASE; TESTOSTERONE; UNCLASSIFIED DRUG; ANTIOXIDANT;

ABACOPTERIS PENANGIANA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MEDICINAL PLANT; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RAT; TRADITIONAL MEDICINE; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FERN; GENE EXPRESSION REGULATION; INFLAMMATION; ISOLATION AND PURIFICATION; PATHOLOGY; PROSTATIC HYPERPLASIA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MEDICINE, TRADITIONAL; OXIDATIVE STRESS; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; PTERIDOPHYTA; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 84907893298     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2014.09.025     Document Type: Article

References (50)

1. Administration Bureau of National Chinese Traditional Medicine Chinese Herbal 1998 Shanghai Scientific and Technical Publishers Shanghai 164
2. B. Alberto, C. Umberto, S. Nazareno, G. Andrea, S. Andera, B. Marco, T. Manuela, G. Valerio, G. Giorgio, R. Patriaio, and M. Francesco Benign prostatic hyperplasia and its aetiologies European Association of Urology 8 2009 865 871
3. G. Agati, E. Azzarello, S. Pollastri, and M. Tattini Flavonoids as antioxidants in plants: location and functional significance Plant Science 196 2012 67 76
4. J.T. Anim, C. Udo, and B. John Characterisation of inflammatory cells in benign prostatic hyperplasia Acta Histochemica 100 1998 439 449
5. S. Aquila, R.M. Giner, M.C. Recio, E.D. Spegazzini, and J.L. Rios Anti-inflammatory activity of flavonoids from Cayaponia tayuya roots Journal of Ethnopharmacology 121 2009 333 337
6. R.T. Atawia, M.G. Tadros, A.E. Khalifa, H.A. Mosli, and A.B. Abdel-Naim Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats Toxicology Letter 219 2013 160 169
7. P.A. Baeuerle, and T. Henkel Function and activation of NF-kappa B in the immune system Annual Review of Immunology 12 1994 141 179
8. P. Boyle, and P. Napalkov Epidemiology of benign prostatic hyperplasia: current perspectives European Urology 29 1996 7 11
9. A. Briganti, U. Capitanio, N. Suardi, A. Gallina, A. Salonia, and M. Bianchi Benign prostatic hyperplasia and its aetiologies European Urology Supplements 8 2009 865 871
10. A.M. De Marzo, E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C.G. Drake, Y. Nakai, W.B. Isaacs, and W.G. Nelson Inflammation in prostate carcinogenesis Nature Reviews Cancer 7 2007 256 269
11. C.A. Dinarello Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist International Reviews Immunology 16 1998 457 499
12. M.T. Flannery, J. Ramsdell, A. Ranhosky, G. Davidai, and G. Ruoff Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting Current Medical Research and Opinion 22 2006 721 730
13. C.L. Foley, and R.S. Kirby 5 alpha-reductase inhibitors: what's new? Current Opinion in Urology 13 2003 31 37
14. K.H. Fouad Serenoa repens: the Scientific basis for the treatment of benign prostatic hyperplasia European Urology Supplements 8 2009 887 893
15. M. Gao, H. Ding, G. Zhong, J. Lu, H. Wang, Q. Li, and Z. Wang The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD, and Zn levels in pretreatment and posttreatment Urology 79 2012 391 396
16. W.M. Garraway, G.N. Collins, and R.J. Lee High prevalence of benign prostatic hypertrophy in the community Lancet 338 1991 469 471
17. T.A. Gossel, and J.R. Wuest New drugs of 2004 for treatment of benign prostatic hyperplasia: Avodart and Uroxatal Continuing Education for Pharmacist 22 2004 1 4
18. S.P. Hehner, M. Heinrich, P.M. Bork, M. Vogt, F. Ratter, V. Lehmann, K. Schulze-Osthoff, W. Dröge, and M.L. Schmitz Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of I-κB-α and IκB-β The Journal of Biological Chemistry 273 1998 1288 1297
19. Y.J. Jeon, B.H. Kim, S. Kim, I. Oh, S. Lee, J. Shin, and T.Y. Kim Rhododendrin ameliorates skin inflammation through inhibition of NF-κB, MAPK,and PI3K/Akt signaling European Journal of Pharmacology 714 2013 7 14
20. H.J. Kim, J.W. Park, Y.S. Cho, C.H. Cho, J.S. Kim, H.W. Shin, D.H. Chung, S.J. Kim, and Y.S. Chun Pathogenic role of HIF-1alpha in prostate hyperplasia in the presence of chronic inflammation Biochimica et Biophysica Acta 1832 2013 183 194
21. N. Kyprianou Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance The Journal of Urology 169 2003 1520 1525
22. N. Kyprianou, H. Tu, and S.C. Jacobs Apoptotic versus proliferative activities in human benign prostatic hyperplasia Human Pathology 27 1996 668 675
23. C.S. Lee, S.A. Lee, Y.J. Kim, S.J. Seo, and M.W. Lee 3,4,5-Tricaffeoylquinic acid inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways International Immunopharmacology 11 2011 1715 1723
24. K.L. Lee, and D.M. Peehl Molecular and cellular pathogenesis of benign prostatic hyperplasia The Journal of Urology 172 2004 1784 1791
25. Y.F. Li, L.P. Tang, R.R. He, Z. Xu, Q.Q. He, F.J. Xiang, W.W. Su, and H. Kurihara Anthocyanins extract from bilberry enhances the therapeutic effect of pollen of Brassica napus L. on stress-provoked benign prostatic hyperplasia in restrained mice Journal of Functional Foods 5 2013 1357 1365
26. Y.L. Lin, S.H. Tsai, S.Y. Lin-Shiau, C.T. Ho, and J.K. Lin Theaflavin-3,3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-κB in macrophages European Journal of Pharmacology 367 1999 379 388
27. F. Lotti, and M. Maggi Interleukin 8 and the male genital tract Journal of Reproductive Immunology 100 2013 54 65
28. F. Manzarbeitia, R. Vela Navarrete, and M.J. Fernandez-Acenero Early histopathological aspects of benign prostatic hyperplasia: myxoid-inflammatory nodules Actas Urologicas Espanolas 34 2010 549 554
29. L.D. McLaren, T.J. Jerde, and W. Bushman Role of interleukins, IGF and stemcells in BPH Differentiation 82 2011 237 243
30. M.M. Mortenson, M.G. Schlieman, S. Virudalchalam, and R.J. Bold Overexpression of BCL-2 results in activation of the AKT/NF-kB Cell survival pathway Journal of Surgical Research 114 2003 302
31. K.G. Naber, and W. Weidner Chronic prostatitis-an infectious disease? Journal of Antimicrobial Chemotherapy 46 2000 157 161
32. P. Napalkov, P. Maisonneuve, and P. Boyle Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia Urology 46 1995 41 46
33. J.C. Nickel, J. Downey, I. Young, and S. Boag Asymptomatic inflammation and/or infection in benign prostatic hyperplasia BJU International 84 1999 976 981
34. G.S. Palapattu, S. Sutcliffe, P.J. Bastian, E.A. Platz, A.M. De Marzo, W.B. Isaacs, and W.G. Nelson Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis 26 2005 1170 1181
35. W. Qu, Q.M. Zhang, J.M. Jia, W.Q. Yu, W.C. Wang, S.S. Liu, H.H. He, L.F. Chen, R.W. Wang, and S. Lu Clinical efficacy observation of Huang'e capsule on benign prostatic hyperplasia with Qi-deficiency and blood-stasis, dampness-heat and blood-stasis syndrome Chinese Journal of Modern Applied Pharmacy 29 2012 749 752
36. G. Robert, A.L. Descazeaud, Y. Allory, F. Vacherot, and A. Taille Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? European Urology Supplements 8 2009 879 886
37. J.M. Schenk, A.R. Kristal, M.L. Neuhouser, C.M. Tangen, E. White, D.W. Lin, M. Kratz, and I.M. Thompson Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial American Journal of Epidemiology 171 2010 571 582
38. A. Sciarra, F. Di Silverio, S. Salciccia, A.M. Autran Gomez, A. Gentilucci, and V. Gentile Inflammation and chronic prostatic diseases: evidence for a link? European Urology 52 2007 964 972
39. A. Sciarra, G. Mariotti, S. Salciccia, A. Autran Gomez, S. Monti, V. Toscano, and F. Di Silverio Prostate growth and inflammation The Journal of Steroid Biochemistry and Molecular Biology 108 2008 254 260
40. F.D. Silverioa, C. Bosmanb, M. Salvatoric, L. Albanesia, L.P. Pannunzic, M. Ciccarielloa, A. Cardia, G. Salvatoria, and A. Sciarra Combinationtherapy with rofecoxib and finasteride in the treatment of men with lower urinarytract symptoms (LUTS) and benign prostatic hyperplasia (BPH) European Urology 47 2005 72 79
41. D.A. Shoskes Phytotherapy in chronic prostatitis Urology 60 2002 35 37
42. G.E. Steiner, M.E. Newman, D. Paikl, U. Stix, N. Memaran-Dagda, C. Lee, and M.J. Marberger Expression and function of pro-inflammatory inter- leukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate Prostate 56 2002 171 182
43. G.E. Steiner, U. Stix, A. Handisurya, M. Willheim, A. Haitel, F. Reithmayr, D. Paikl, R.C. Ecker, K. Hrachowitz, G. Kramer, C. Lee, and M. Marberger Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue Laboratory Investigation 83 2003 1131 1146
44. H. Sun, T.J. Li, L.N. Sun, Y. Qiu, B.B. Huang, B. Yi, and W.S. Chen Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats Journal of Ethnopharmacology 115 2008 203 208
45. J.M. Taylor, P.J. Crack, J.A. Gould, U. Ali, P.J. Hertzog, and R.C. Iannello Akt phosphorylation and NFkappaB activation are counterregulated under conditions of oxidative stress Experimental Cell Research 300 2004 463 475
46. C. Wang, H. Duan, and L. He Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro European Journal of Pharmacology 612 2009 143 152
47. L. Wang, J.R. Yang, L.Y. Yang, and Z.T. Liu Chronic inflammation in benign prostatic hyperplasia: implications for therapy Medical Hypotheses 70 2008 1021 1023
48. H. Wei, G. Wu, D. Shi, S. Song, X. Zhang, Y. Lei, and J. Ruan Total flavan glycoside from Abacopteris penangiana rhizomes and its acid hydrolysate: characterisation and anti-benign prostatic hyperplasia potential Food Chemistry 134 2012 1959 1966
49. X. Yang, L. Yuan, J. Chen, C. Xiong, and J. Ruan Multitargeted protective effect of Abacopteris penangiana against carrageenan-induced chronic prostatitis in rats Journal of Ethnopharmacology 151 2014 343 351
50. Q. Zhou, U. Mrowietz, and M. Rostami-Yazdi Oxidative stress in the pathogen- esis of psoriasis Free Radical Biology & Medicine 47 2009 891 905